Smoldering Multiple Myeloma: all 101 studies
Page 1 of 2. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.
- Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA FragmentomicsNot yet recruitingNCT07684274
- FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseRecruitingNCT07446777Not applicable
- A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)RecruitingNCT07393282Phase 3
- Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot StudyNot yet recruitingNCT07305662Not applicable
- Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical EvolutionRecruitingNCT07214324
- A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple MyelomaRecruitingNCT07069751Not applicable
- Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant BiomarkersNot yet recruitingNCT06987708Not applicable
- Whole Body MRI in OncologyRecruitingNCT06895291
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
- Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering MyelomaRecruitingNCT06762769Phase 2
- CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot StudyRecruitingNCT06644625
- Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaRecruitingNCT06574126Phase 2
- Promoting Diagnosis and Management of AL in Italy (ProDigALIty)RecruitingNCT06383143
- Screening for AL Amyloidosis in Smoldering Multiple MyelomaRecruitingNCT06365060
- European Myeloma Network (EMN) Sample ProjectRecruitingNCT06237803
- Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight TrialRecruitingNCT06212323
- A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple MyelomaRecruitingNCT06140524Phase 2
- A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)RecruitingNCT06055894Not applicable
- The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple MyelomaRecruitingNCT05841550Phase 1/2
- A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)RecruitingNCT05640843Not applicable
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple MyelomaRecruitingNCT05597345Phase 2
- Immuno-PRISM (PRecision Intervention Smoldering Myeloma)RecruitingNCT05469893Phase 2
- Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor ConditionsRecruitingNCT05361694
- Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple MyelomaRecruitingNCT05312255Not applicable
- A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFHRecruitingNCT05283993
- Quality of Life in Patients With Asymptomatic Monoclonal GammopathiesRecruitingNCT05136807
- Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple MyelomaRecruitingNCT04776395Phase 2
- Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaRecruitingNCT03937635Phase 3
- A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)Enrolling by invitationNCT03815279Phase 2
- Registry for Adults With Plasma Cell Disorders (PCD's)RecruitingNCT03717844
- The Indiana Myeloma RegistryRecruitingNCT03616483
- Observational Prospective Research Study In Monoclonal Gammopathies leadINg to MyelomaRecruitingNCT02726750
- Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
- PROFAST Intervention in Precursor Multiple MyelomaCompletedNCT05565638Not applicableResults posted
- Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple MyelomaTerminatedNCT05288062Phase 2Results posted
- A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)Active, not recruitingNCT04920084Not applicableResults posted
- Investigation of Metformin for the Prevention of Progression of Precursor Multiple MyelomaActive, not recruitingNCT04850846Phase 2Results posted
- Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate CancerCompletedNCT04731844Phase 2Results posted
- The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone LossCompletedNCT03951220Results posted
- Denosumab for Smoldering Multiple MyelomaCompletedNCT03839459Phase 2Results posted
- A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple MyelomaCompletedNCT03301220Phase 3Results posted
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple MyelomaActive, not recruitingNCT03236428Phase 2Results posted
- Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma PatientsTerminatedNCT02943473Phase 2Results posted
- Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple MyelomaCompletedNCT02916771Phase 2Results posted
- A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
- Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT02603887Early Phase 1Results posted
- Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple MyelomaCompletedNCT02492750Phase 1Results posted
- Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaTerminatedNCT02353572Phase 1/2Results posted
- A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple MyelomaCompletedNCT02316106Phase 2Results posted
- E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaCompletedNCT02279394Phase 2Results posted
- UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple MyelomaCompletedNCT01884688Phase 2Results posted
- A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple MyelomaCompletedNCT01484275Phase 2Results posted
- Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaCompletedNCT01441973Phase 2Results posted
- A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic MyelomaTerminatedNCT01302366Phase 2Results posted
- A Phase II Trial of Anti-KIR in Smoldering Multiple MyelomaTerminatedNCT01248455Phase 2Results posted
- Imaging in MGUS, SMM and MMCompletedNCT01237054Phase 2Results posted
- Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple MyelomaCompletedNCT01222286Phase 2Results posted
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT01169337Phase 3Results posted
- Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic MyelomaTerminatedNCT01096810Phase 2Results posted
- Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma PatientsTerminatedNCT00983346Phase 2Results posted
- Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple MyelomaTerminatedNCT00942422Phase 2Results posted
- Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)TerminatedNCT00899353Phase 2Results posted
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell TransplantActive, not recruitingNCT00114101Phase 3Results posted
- Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00112827Phase 1/2Results posted
- Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering MyelomaCompletedNCT00099047Phase 2Results posted
- A Real-world Study in Participants With Smoldering Multiple MyelomaCompletedNCT06472778
- Use of Elranatamab in Patients With High-risk Smoldering Multiple MyelomaActive, not recruitingNCT06183489Phase 2
- A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple MyelomaActive, not recruitingNCT05955508Phase 2
- Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation ProgramActive, not recruitingNCT05831358Not applicable
- CAR- PRISM (PRecision Intervention Smoldering Myeloma)Active, not recruitingNCT05767359Phase 2
- Biology and Genetics of Smouldering MyelomaStatus unknownNCT05047107
- Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American PatientsActive, not recruitingNCT05014646Phase 2
- MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) SurveyStatus unknownNCT04727294
- Screening to Improve Survival in AL AmyloidosisCompletedNCT04615572
- Leflunomide for the Treatment of High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT04370483Early Phase 1
- Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.Active, not recruitingNCT04144387Not applicable
- Leflunomide in Treating Patients With High-Risk Smoldering Multiple MyelomaWithdrawnNCT03952832Phase 2
- PD-L1 Peptide Vaccination in High Risk Smoldering Multiple MyelomaTerminatedNCT03850522Phase 2
- Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMMActive, not recruitingNCT03673826Phase 2
- Personalized Vaccine in Treating Patients With Smoldering Multiple MyelomaCompletedNCT03631043Early Phase 1
- Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering MyelomaWithdrawnNCT03591614Early Phase 1
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantActive, not recruitingNCT03289299Phase 2
- Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)Active, not recruitingNCT02960555Phase 2
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMActive, not recruitingNCT02886065Phase 1
- Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic MyelomaTerminatedNCT02784483Phase 1
- Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyCompletedNCT02697383Phase 1
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic CancerStatus unknownNCT02240537Phase 1
- Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple MyelomaCompletedNCT01955395Not applicable
- A Phase II Study of BI-505 in Smoldering Multiple MyelomaTerminatedNCT01838369Phase 2
- Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple MyelomaCompletedNCT01718899Phase 1
- MLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaWithdrawnNCT01660997Phase 2
- Imaging Studies and the Development of Multiple MyelomaWithdrawnNCT01571726Phase 2
- Study of BHQ880 in Patients With High Risk Smoldering Multiple MyelomaCompletedNCT01302886Phase 2
- A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple MyelomaCompletedNCT01219010Phase 1
- Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersActive, not recruitingNCT01177527
- Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)TerminatedNCT01109407
- Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.TerminatedNCT01079429
- S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.CompletedNCT00919139
- Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple MyelomaWithdrawnNCT00503763Phase 2